Blog
RSS FeedPosted by Michael Wonder on 31 Aug 2025
FDA approval of Leqembi subcutaneous formulation charts path to combination therapies for Alzheimer's disease
29 August 2025 - Subcutaneous delivery increases accessibility and introduces potential for at home administration, following model of diabetes and ...
Posted by Michael Wonder on 13 Apr 2022
NICE backs Biogen’s Vumerity for multiple sclerosis
13 April 2022 - Patients with relapsing-remitting multiple sclerosis in England, Wales and Northern Ireland can now access treatment with ...
Posted by Michael Wonder on 13 Apr 2022
Why the drug pricing debate is focused on insulin
13 April 2022 - The treatment has been around for over a century but insulin has still become the centre ...
Posted by Michael Wonder on 13 Apr 2022
Committee releases report uncovering significant conflicts of interest at McKinsey related to work for FDA and opioid manufacturers
13 April 2022 - Chairwoman Maloney calls on McKinsey’s global managing partner to testify at public hearing. ...
Posted by Michael Wonder on 13 Apr 2022
FDA takes important steps to increase racial and ethnic diversity in clinical trials
13 April 2022 - Agency’s focus on inclusion in trials for all medical products aligns with Biden Administration’s cancer moonshot goal ...
Posted by Michael Wonder on 13 Apr 2022
Pear Therapeutics receives safer technologies program designation from FDA for product candidate to treat acute and chronic pain
13 April 2022 - Pear Therapeutics today announced it has received safer technologies program for medical devices designation from the ...
Posted by Michael Wonder on 13 Apr 2022
European Commission approves Padcev (enfortumab vedotin) for locally advanced or metastatic urothelial cancer
13 April 2022 - Enfortumab vedotin is the first medicine approved in the EU for patients who received a prior ...
Posted by Michael Wonder on 13 Apr 2022
BriaCell receives FDA fast track approval for targeted breast cancer immunotherapy
13 April 2022 BriaCell is currently enrolling and dosing advanced breast cancer patients in a Phase I/IIa study, now with ...
Posted by Michael Wonder on 13 Apr 2022
ICER releases draft evidence report on gene therapy for beta thalassaemia
13 April 2022 - Public comment period now open until 10 May 2022; requests to make oral comment during public ...
Posted by Michael Wonder on 13 Apr 2022
Daratumumab monotherapy for treating relapsed and refractory multiple myeloma
13 April 2022 - NICE has published evidence based recommendations on the use of daratumumab (Darzalex) for the treatment of ...
Posted by Michael Wonder on 13 Apr 2022
Highest risk COVID-19 patients receive ‘brilliant’ new antivirals at home
9 April 2022 - Thousands of patients with COVID-19 who are most likely to be admitted to hospital are receiving ...
Posted by Michael Wonder on 13 Apr 2022
TGA approves Lumakras
13 April 2022 - Sotorasib is a Kirsten rat sarcoma (KRAS) G12C inhibitor, which covalently and irreversibly binds to the unique ...
Posted by Michael Wonder on 12 Apr 2022
US FDA grants fast track designation for Paradigm’s Phase 3 osteoarthritis program
12 April 2022 - Paradigm Biopharmaceuticals is pleased to announce that the U.S. FDA has granted fast track designation for ...
Posted by Michael Wonder on 12 Apr 2022
Health Canada has approved Zeposia (ozanimod), an oral treatment for adults with moderately to severely active ulcerative colitis
12 April 2022 - Zeposia is the first and only S1P receptor modulating agent approved for the treatment of ulcerative ...
Posted by Michael Wonder on 12 Apr 2022
Jardiance (empagliflozin) becomes the first and only approved treatment in Canada for adults with chronic heart failure regardless of ejection fraction
12 April 2022 - Jardiance is the first and only heart failure therapy to demonstrate a statistically significant risk reduction in ...
Posted by Michael Wonder on 12 Apr 2022
EMA and the EUnetHTA 21 consortium set priorities for their collaboration
12 April 2022 - The EMA and the European Network for Health Technology Assessment (EUnetHTA) 21 consortium have published a joint ...